These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

554 related articles for article (PubMed ID: 36402595)

  • 1. Immunogenicity and Safety of SpikoGen, an Adjuvanted Recombinant SARS-CoV-2 Spike Protein, as a Heterologous Third Booster Dose in Kidney Transplant Patients: A Single-arm Clinical Trial.
    Nafar M; Mostafaloo N; Firouzan A; Poorrezagholi F; Samadian F; Dalili N; Barati S; Anjidani N; Kafi H; Shahpari R; Bayat M; Kianipour S; Samavat S
    Clin Ther; 2022 Dec; 44(12):1566-1576. PubMed ID: 36402595
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity and safety of SpikoGen®, an adjuvanted recombinant SARS-CoV-2 spike protein vaccine as a homologous and heterologous booster vaccination: A randomized placebo-controlled trial.
    Tabarsi P; Anjidani N; Shahpari R; Roshanzamir K; Fallah N; Andre G; Petrovsky N; Barati S
    Immunology; 2022 Nov; 167(3):340-353. PubMed ID: 35758850
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and immunogenicity of SpikoGen®, an Advax-CpG55.2-adjuvanted SARS-CoV-2 spike protein vaccine: a phase 2 randomized placebo-controlled trial in both seropositive and seronegative populations.
    Tabarsi P; Anjidani N; Shahpari R; Mardani M; Sabzvari A; Yazdani B; Roshanzamir K; Bayatani B; Taheri A; Petrovsky N; Li L; Barati S
    Clin Microbiol Infect; 2022 Sep; 28(9):1263-1271. PubMed ID: 35436611
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative immunogenicity and safety of SpikoGen®, a recombinant SARS-CoV-2 spike protein vaccine in children and young adults: An immuno-bridging clinical trial.
    Tabarsi P; Mamishi S; Anjidani N; Shahpari R; Kafi H; Fallah N; Yazdani B; Ebrahimi A; Roshanzamir K; Ebrahimi H; Oveisi S; Soltani A; Petrovsky N; Barati S
    Int Immunopharmacol; 2024 Jan; 127():111436. PubMed ID: 38147778
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ability of SpikoGen®, an Advax-CpG adjuvanted recombinant spike protein vaccine, to induce cross-neutralising antibodies against SARS-CoV-2 variants.
    Honda-Okubo Y; Antipov A; Andre G; Barati S; Kafi H; Petrovsky N
    Immunology; 2023 Oct; 170(2):193-201. PubMed ID: 37199229
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical development of SpikoGen®, an Advax-CpG55.2 adjuvanted recombinant spike protein vaccine.
    Petrovsky N
    Hum Vaccin Immunother; 2024 Dec; 20(1):2363016. PubMed ID: 38839044
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial.
    Mallory RM; Formica N; Pfeiffer S; Wilkinson B; Marcheschi A; Albert G; McFall H; Robinson M; Plested JS; Zhu M; Cloney-Clark S; Zhou B; Chau G; Robertson A; Maciejewski S; Hammond HL; Baracco L; Logue J; Frieman MB; Smith G; Patel N; Glenn GM;
    Lancet Infect Dis; 2022 Nov; 22(11):1565-1576. PubMed ID: 35963274
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Post-Hoc Analysis of Potential Correlates of Protection of a Recombinant SARS-CoV-2 Spike Protein Extracellular Domain Vaccine Formulated with Advax-CpG55.2-Adjuvant.
    Petrovsky N
    Int J Mol Sci; 2024 Aug; 25(17):. PubMed ID: 39273405
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluating the efficacy and safety of SpikoGen®, an Advax-CpG55.2-adjuvanted severe acute respiratory syndrome coronavirus 2 spike protein vaccine: a phase 3 randomized placebo-controlled trial.
    Tabarsi P; Anjidani N; Shahpari R; Mardani M; Sabzvari A; Yazdani B; Kafi H; Fallah N; Ebrahimi A; Taheri A; Petrovsky N; Barati S
    Clin Microbiol Infect; 2023 Feb; 29(2):215-220. PubMed ID: 36096430
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Developmental and reproductive safety of Advax-CpG55.2™ adjuvanted COVID-19 and influenza vaccines in mice.
    Sakala IG; Honda-Okubo Y; Petrovsky N
    Vaccine; 2023 Sep; 41(41):6093-6104. PubMed ID: 37659896
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and immunogenicity of COReNAPCIN, a SARS-CoV-2 mRNA vaccine, as a fourth heterologous booster in healthy Iranian adults: A double-blind, randomized, placebo-controlled, phase 1 clinical trial with a six-month follow-up.
    Salehi M; Alavi Darazam I; Nematollahi A; Alimohammadi M; Pouya S; Alimohammadi R; Khajavirad N; Porgoo M; Sedghi M; Mahdi Sepahi M; Azimi M; Hosseini H; Mahmoud Hashemi S; Dehghanizadeh S; Khoddami V
    Int Immunopharmacol; 2024 Jun; 134():112192. PubMed ID: 38761778
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Covax-19/Spikogen® vaccine based on recombinant spike protein extracellular domain with Advax-CpG55.2 adjuvant provides single dose protection against SARS-CoV-2 infection in hamsters.
    Li L; Honda-Okubo Y; Baldwin J; Bowen R; Bielefeldt-Ohmann H; Petrovsky N
    Vaccine; 2022 May; 40(23):3182-3192. PubMed ID: 35465982
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of age and gender on immunogenicity and reactogenicity of SpikoGen recombinant spike protein vaccine: a post-hoc analysis.
    Anjidani N; Shahpari R; Kafi H; Petrovsky N; Barati S
    Sci Rep; 2024 Sep; 14(1):22631. PubMed ID: 39349494
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity and safety of single booster dose of KD-414 inactivated COVID-19 vaccine in adults: An open-label, single-center, non-randomized, controlled study in Japan.
    Terada-Hirashima J; Takamatsu Y; Shimizu Y; Uemura Y; Takeuchi JS; Tomita N; Matsuda K; Maeda K; Yamamoto S; Fukunaga A; Ohmagari N; Mikami A; Sonoda K; Ujiie M; Mitsuya H; Sugiura W
    Hum Vaccin Immunother; 2023 Dec; 19(1):2193074. PubMed ID: 37052247
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity and safety of RAZI recombinant spike protein vaccine (RCP) as a booster dose after priming with BBIBP-CorV: a parallel two groups, randomized, double blind trial.
    Erfanpoor S; Banihashemi SR; Mokhbaeralsafa L; Kalantari S; Es-Haghi A; Nofeli M; Rezaei Mokarram A; Sadeghi F; Hajimoradi M; Razaz SH; Taghdiri M; Lotfi M; Khorasani A; Ansarifar A; Masoumi S; Mohazzab A; Filsoof S; Mohseni V; Shahsavan M; Gharavi N; Setarehdan SA; Rabiee MH; Fallah Mehrabadi MH; Solaymani-Dodaran M
    BMC Med; 2024 Feb; 22(1):78. PubMed ID: 38378570
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial.
    Chen GL; Li XF; Dai XH; Li N; Cheng ML; Huang Z; Shen J; Ge YH; Shen ZW; Deng YQ; Yang SY; Zhao H; Zhang NN; Zhang YF; Wei L; Wu KQ; Zhu MF; Peng CG; Jiang Q; Cao SC; Li YH; Zhao DH; Wu XH; Ni L; Shen HH; Dong C; Ying B; Sheng GP; Qin CF; Gao HN; Li LJ
    Lancet Microbe; 2022 Mar; 3(3):e193-e202. PubMed ID: 35098177
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity, durability, and safety of an mRNA and three platform-based COVID-19 vaccines as a third dose following two doses of CoronaVac in China: A randomised, double-blinded, placebo-controlled, phase 2 trial.
    Zhang Y; Ma X; Yan G; Wu Y; Chen Y; Zhou Z; Wan N; Su W; Liu FW; Dai MX; Yang M; Li C; Yu X; Zhang L; Wang Z; Zhou TC; You D; Wei J; Zhang Z;
    EClinicalMedicine; 2022 Dec; 54():101680. PubMed ID: 36188435
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: interim results of a randomised, placebo-controlled, phase 1-2, dose-ranging study.
    Goepfert PA; Fu B; Chabanon AL; Bonaparte MI; Davis MG; Essink BJ; Frank I; Haney O; Janosczyk H; Keefer MC; Koutsoukos M; Kimmel MA; Masotti R; Savarino SJ; Schuerman L; Schwartz H; Sher LD; Smith J; Tavares-Da-Silva F; Gurunathan S; DiazGranados CA; de Bruyn G
    Lancet Infect Dis; 2021 Sep; 21(9):1257-1270. PubMed ID: 33887209
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial.
    Wu S; Huang J; Zhang Z; Wu J; Zhang J; Hu H; Zhu T; Zhang J; Luo L; Fan P; Wang B; Chen C; Chen Y; Song X; Wang Y; Si W; Sun T; Wang X; Hou L; Chen W
    Lancet Infect Dis; 2021 Dec; 21(12):1654-1664. PubMed ID: 34324836
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.